Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Binnewies M, Krummel MF et al. Cell. 2019

A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Barry KC, Krummel MF et al. Nature Medicine. 2018

Understanding the tumor immune microenvironment (TIME) for effective therapy. Binnewies M, Krummel MF et al. Nature Medicine. 2018

Partially exhausted tumor-infiltrating lymphocytes predict response to combination Immunotherapy. Loo K, Daud AI et al. JCI Insight. 2017

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Tumeh PC, Daud AI et al. Cancer Immunol Res. 2017

Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine. Boldajipour B, Krummel MF et al. JCI Insight. 2016

Tracking the Spatial and Functional Gradient of Monocyte-To-Macrophage Differentiation in Inflamed Lung. Sen D, Krummel MF et al. PLoS One. 2016

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. Daud AI, Rosenblum MD et al. J Clin Invest. 2016

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Roberts EW, Krummel MF et al. Cancer Cell. 2016

Visualization of immediate immune responses to pioneer metastatic cells in the lung. Headley MB, Krummel MF et al. Nature. 2016

T cell migration, search strategies and mechanisms. Krummel MF, Gérard A et al. Nat Rev Immunol. 2016

The emerging understanding of myeloid cells as partners and targets in tumor rejection. Broz ML, Krummel MF. Cancer Immunol Res. 2015

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Broz ML, Krummel MF et al. Cancer Cell. 2014